DOE OSTI · 23200820
Overview and Lessons From the Preclinical Chemoradiotherapy Testing Consortium
Abstract
In the current molecular-targeted cancer treatment era, many new agents are being developed so that optimizing therapy with a combination of radiation and drugs is complex. The use of emerging laboratory technologies to further biological understanding of drug-radiation mechanisms of action will enhance the efficiency of the progression from preclinical studies to clinical trials. In 2017, the National Cancer Institute (NCI) solicited proposals through PAR 16-111 to conduct preclinical research combining targeted anticancer agents in the Cancer Therapy Evaluation Program's portfolio with chemoradiation.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Coleman, C. Norman, Bernhard, Eric J., Espey, Michael G., Vikram, Bhadrasain. 2021-12-15. Overview and Lessons From the Preclinical Chemoradiotherapy Testing Consortium. https://doi.org/10.1016/j.ijrobp.2021.07.1709
Cite the original work for its findings. Save a collection to share your selection of sources.